Publications by authors named "Mosufa Zainab"
Article Synopsis
- GM1 gangliosidosis (GM1) is a lysosomal disorder caused by mutations in the GLB1 gene, leading to serious neurodegeneration and currently has no approved treatments.
- A study involving 41 patients with type II GM1 revealed distinct genetic variants and observed that many children had normal hearing and did not exhibit typical symptoms seen in type I GM1.
- The research highlighted progressive brain atrophy and identified crucial correlations between brain chemistry changes and patient behavior scores, emphasizing the importance of this long-term study for improving diagnosis and developing future therapies.
Article Synopsis
- GM1 gangliosidosis is a rare genetic disease mainly affecting children, characterized by neurodegeneration, and currently has no approved treatments but is under investigation through gene therapy and other trials.
- A study involving 41 individuals with type II GM1 assessed various health factors, revealing unique characteristics and differences compared to type I infantile forms, such as normal hearing and specific heart issues in older children.
- The study provided new insights into the disease's progression and aimed to correct misunderstandings about type II GM1, enhancing the knowledge base for future diagnosis and treatment approaches.
The ESKAPE pathogens comprise a group of multidrug-resistant bacteria that are the leading cause of nosocomial infections worldwide. The prevalence of antibiotic resistant strains and the relative ease by which bacteria acquire resistance genes highlight the continual need for the development of novel antibiotics against new drug targets. The methylerythritol phosphate (MEP) pathway is an attractive target for the development of new antibiotics.
View Article and Find Full Text PDFFosmidomycin inhibits IspC (1-deoxy-d-xylulose 5-phosphate reductoisomerase), the first committed enzyme in the methylerythritol phosphate (MEP) pathway of isoprenoid biosynthesis. The MEP pathway of isoprenoid biosynthesis is essential to the causative agent of the plague, , and is entirely distinct from the corresponding mammalian pathway. To further drug development, we established structure-activity relationships of fosmidomycin analogues by assessing a suite of 17 α-phenyl-substituted reverse derivatives of fosmidomycin against IspC.
View Article and Find Full Text PDF